Novartis Reports Results of Cosentyx (secukinumab) in P-III Study in Patients with Moderate to Severe Plaque Psoriasis in China

 Novartis Reports Results of Cosentyx (secukinumab) in P-III Study in Patients with Moderate to Severe Plaque Psoriasis in China

Novartis Reports Results of Cosentyx (secukinumab) in P-III Study in Patients with Moderate to Severe Plaque Psoriasis in China

Shots:

  •  The P-III study involves assessing Cosentyx (secukinumab, 150mg & 300mg) in 543 patients with moderate to severe plaque psoriasis in China
  • The P-III study results: PASI 75 & PASI 90 (97.7% & 80.9%) @12 wks. @300mg; PASI 90 (87%) @16wks. @300mg; PASI 75 & PASI 90 (87.8% & 66.4%) @12wks @150mg. The results presented at the American Academy of Dermatology (AAD) Annual Meeting
  • Cosentyx (secukinumab) is a mAb targeting IL-17A responsible for inflammation and development of psoriatic diseases and has approved in more than 80 countries including EU & the US

Click here to read full press release/ article | Ref: Novartis | Image: Business Insider

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post